Abcellera posts ABCL635 Phase 2 clinical update presentation on menopause hot flashes
ABCL•Phase 2 update for ABCL635 in menopausal vasomotor symptoms
Abcellera released a Phase 2 clinical update presentation for ABCL635 in moderate-to-severe menopausal vasomotor symptoms.
- Week 4 data showed an 83% reduction in moderate-to-severe VMS frequency vs. 33% for placebo; placebo-adjusted difference 50%.
- VMS severity score fell 58% vs. 12% for placebo at week 4; placebo-adjusted difference 46%.
- Safety summary showed no serious or grade 3+ adverse events in the ABCL635 arm; one mild transaminase increase resolved within one week.
- Next steps include completing 12-week follow-up to support dose selection, then regulatory talks on late-stage development in menopause and oncology settings.
